Chase Knickerbocker
Stock Analyst at Craig-Hallum
(4.63)
# 180
Out of 5,058 analysts
47
Total ratings
61.7%
Success rate
31.06%
Average return
Main Sectors:
Stocks Rated by Chase Knickerbocker
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HROW Harrow | Maintains: Buy | $54 → $64 | $37.66 | +69.94% | 4 | Sep 23, 2025 | |
| INDV Indivior | Maintains: Buy | $27 → $34 | $31.77 | +7.02% | 5 | Aug 27, 2025 | |
| FENC Fennec Pharmaceuticals | Maintains: Buy | $13 → $14 | $7.86 | +78.23% | 6 | Aug 15, 2025 | |
| PYPD PolyPid | Maintains: Buy | $15 → $13 | $3.63 | +258.13% | 2 | Aug 14, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $6.5 → $11 | $6.84 | +60.82% | 2 | Aug 8, 2025 | |
| DMAC DiaMedica Therapeutics | Maintains: Buy | $8 → $11 | $7.22 | +52.35% | 1 | Jul 18, 2025 | |
| BFLY Butterfly Network | Initiates: Buy | $3 | $2.31 | +29.87% | 1 | Jul 1, 2025 | |
| NRXS NeurAxis | Initiates: Buy | $7 | $2.51 | +178.88% | 1 | Jun 16, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $12 → $17 | $14.37 | +18.30% | 3 | Jun 9, 2025 | |
| ETON Eton Pharmaceuticals | Maintains: Buy | $26 → $28 | $16.30 | +71.78% | 6 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $39 | $16.86 | +131.32% | 1 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $8 | $3.19 | +151.18% | 4 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $21 | $8.14 | +157.99% | 2 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $6 | $4.42 | +35.75% | 2 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $12 | $6.54 | +83.49% | 2 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $6.31 | +58.60% | 1 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $23 | $22.94 | +0.26% | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1 → $1.2 | $0.65 | +85.19% | 2 | Jul 11, 2023 |
Harrow
Sep 23, 2025
Maintains: Buy
Price Target: $54 → $64
Current: $37.66
Upside: +69.94%
Indivior
Aug 27, 2025
Maintains: Buy
Price Target: $27 → $34
Current: $31.77
Upside: +7.02%
Fennec Pharmaceuticals
Aug 15, 2025
Maintains: Buy
Price Target: $13 → $14
Current: $7.86
Upside: +78.23%
PolyPid
Aug 14, 2025
Maintains: Buy
Price Target: $15 → $13
Current: $3.63
Upside: +258.13%
Xeris Biopharma Holdings
Aug 8, 2025
Maintains: Buy
Price Target: $6.5 → $11
Current: $6.84
Upside: +60.82%
DiaMedica Therapeutics
Jul 18, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $7.22
Upside: +52.35%
Butterfly Network
Jul 1, 2025
Initiates: Buy
Price Target: $3
Current: $2.31
Upside: +29.87%
NeurAxis
Jun 16, 2025
Initiates: Buy
Price Target: $7
Current: $2.51
Upside: +178.88%
Phathom Pharmaceuticals
Jun 9, 2025
Maintains: Buy
Price Target: $12 → $17
Current: $14.37
Upside: +18.30%
Eton Pharmaceuticals
May 14, 2025
Maintains: Buy
Price Target: $26 → $28
Current: $16.30
Upside: +71.78%
Feb 28, 2025
Initiates: Buy
Price Target: $39
Current: $16.86
Upside: +131.32%
Jan 22, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $3.19
Upside: +151.18%
Jan 17, 2025
Maintains: Buy
Price Target: $18 → $21
Current: $8.14
Upside: +157.99%
Jan 17, 2025
Maintains: Buy
Price Target: $5 → $6
Current: $4.42
Upside: +35.75%
Aug 1, 2024
Maintains: Buy
Price Target: $14 → $12
Current: $6.54
Upside: +83.49%
Jul 11, 2024
Initiates: Buy
Price Target: $10
Current: $6.31
Upside: +58.60%
May 9, 2024
Maintains: Buy
Price Target: $22 → $23
Current: $22.94
Upside: +0.26%
Jul 11, 2023
Maintains: Buy
Price Target: $1 → $1.2
Current: $0.65
Upside: +85.19%